View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Chop Continues; Nasdaq 100 Testing Major Resistance We maintain our near-term bullish outlook on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we went to neutral. We will stay near-term bullish as long as crucial support levels of 6824 on SPX, $610 on QQQ, and $245 on IWM continue to hold. We see mild deterioration in market dynamics, which may provide a near-term headwind; still, MAG7 earning...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

Thermo Fisher Scientific Inc: 2 directors

Two Directors at Thermo Fisher Scientific Inc sold after exercising options/sold 5,696 shares at between 588.265USD and 594.420USD. The significance rating of the trade was 64/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tra...

Moody's Ratings says Thermo Fisher's Clario acquisition expands clinic...

Moody's Ratings commented that Thermo Fisher Scientific Inc.'s (A3 positive) announcement that it entered into a definitive agreement to acquire privately held Clario Holdings, Inc. for $8.88 billion plus certain potential future payouts will add scale and earnings diversity and bolster capabilities...

Thermo Fisher Scientific Inc.: Clario acquisition expands clinical tri...

The acquisition is earnings accretive and enhances the value of services provided to research customers, while increasing leverage by about one-half turn.

Moody's Ratings assigns A3 rating to Thermo Fisher's sr. unsecured not...

Moody's Ratings (Moody's) assigned an A3 rating to the new senior unsecured notes offering by Thermo Fisher Scientific Inc. (Thermo Fisher). There are no changes to Thermo Fisher's existing ratings including the A3 senior unsecured long-term ratings and the senior unsecured commercial paper Prime-2 ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Major Low Likely in Place on S&P 500 In our 2/25/25 Compass, we discussed our expectation for near-term downside as the S&P 500 and Nasdaq 100 (QQQ) displayed several bearish short-term developments. We also said it likely means at least another 2-4 weeks of consolidation, that one or two 8-10% pullbacks in a given year on the SPX is common (even during bull markets), and to not be surprised if there is a test of the bottom of the range at either 5770-5850 or 5600-5670, where we would be buyers...

Moody's Ratings assigns A3 rating to Thermo Fisher's CHF notes; outloo...

Moody's Ratings (Moody's) assigned an A3 rating to the new senior unsecured CHF-denominated notes offering by Thermo Fisher Scientific Inc. (Thermo Fisher). There are no changes to Thermo Fisher's existing ratings including the A3 senior unsecured long-term ratings and the senior unsecured commercia...

Thermo Fisher Scientific Inc.: Update following outlook change to posi...

Our credit view of this issuer reflects its significant scale and good diversification, constrained by its appetite for large acquisitions and shareholder-friendly financial policies

Thermo Fisher Scientific Inc.: Key facts and statistics - 2023

A summary company profile, detailing Thermo Fisher’s business operations and financial highlights.

Moody's assigns A3 rating to Thermo Fisher's CHF notes; outlook stable

Moody's Investors Service ("Moody's") assigned an A3 rating to the new CHF-denominated senior unsecured notes offering by Thermo Fisher Scientific Inc. ("Thermo Fisher"). There are no changes to Thermo Fisher's existing ratings including the A3 senior unsecured long-term ratings and the Prime-2 seni...

Moody's assigns A3 rating to Thermo Fisher's new senior unsecured note...

Moody's Investors Service ("Moody's") assigned an A3 rating to the new senior unsecured notes offering by Thermo Fisher Scientific Inc. ("Thermo Fisher"). There are no changes to Thermo Fisher's existing ratings including the A3 senior unsecured long-term ratings and the senior unsecured commercial ...

Thermo Fisher Scientific Inc.: Good ability to weather near-term headw...

Our credit view of this issuer reflects its strong organic growth prospects, constrained by its shareholder-friendly financial policies including share buybacks and dividends.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch